(Q37139567)

18 August 2017

Antidiabetic action of bezafibrate in a large observational database (English)

1 reference

18 August 2017

0 references

1 reference

ChEBI release 2020-05-28

2

Susan Ellenberg

1 reference

18 August 2017

James H Flory

1

1 reference

18 August 2017

Philippe O Szapary

series ordinal

3

1 reference

18 August 2017

Brian L Strom

series ordinal

4

1 reference

18 August 2017

Sean Hennessy

series ordinal

5

1 reference

18 August 2017

language of work or name

English

0 references

publication date

8 January 2009

1 reference

18 August 2017

1 reference

18 August 2017

32

1 reference

18 August 2017

4

1 reference

18 August 2017

547-551

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

18 August 2017

start time

28 August 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

AMPK and PPARdelta agonists are exercise mimetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Prevention of Type 2 diabetes: fact or fiction?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Global and societal implications of the diabetes epidemic

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

The PPARs: from orphan receptors to drug discovery

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Selling safety--lessons from muraglitazar

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2660490

Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects

3 September 2018

1 reference

12 December 2020

Effect of ciprofibrate on lipoprotien metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype

1 reference

12 December 2020

Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease

1 reference

12 December 2020

Assessing the cardiovascular safety of diabetes therapies

1 reference

12 December 2020

A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia

1 reference

12 December 2020

Identifiers

DOI

10.2337/DC08-1809

1 reference

18 August 2017

1 reference

18 August 2017

1 reference